This clinical trial is focused on studying a condition called neovascular age-related macular degeneration, often referred to as wet AMD. This is a common eye disease that can lead to vision loss in older adults. The study is testing a new treatment approach that combines two medications: OPT-302 and ranibizumab. OPT-302 is a solution for injection that targets specific proteins involved in the growth of abnormal blood vessels in the eye. Ranibizumab is a well-known medication already used to treat wet AMD, and it is also given as an injection into the eye.

The purpose of this study is to evaluate how effective and safe the combination of OPT-302 and ranibizumab is compared to using ranibizumab alone. Participants in the study will receive regular injections of these medications over a period of time. Some participants will receive both OPT-302 and ranibizumab, while others will receive only ranibizumab. There is also a possibility of receiving a placebo, which is an inactive substance. The study will monitor changes in vision and eye health to determine the effectiveness of the treatment.

Throughout the study, participants will have regular check-ups to assess their vision and the condition of their eyes. The study aims to see if the combination of these medications can improve vision more effectively than the standard treatment alone. This research could potentially lead to better treatment options for people with wet AMD, helping to preserve their vision and improve their quality of life.